Oncogenic Roles of Small Nucleolar RNA Host Gene 7 (SNHG7) Long Noncoding RNA in Human Cancers and Potentials

Sajad Najafi¹, Soudeh Ghafouri-Fard², Bashdar Mahmud Hussien³,⁴, Hazha Hadayat Jamal⁵, Mohammad Taheri⁶* and Mohammad Hallajnejad⁷*

¹Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ²Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ³Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Iraq, ⁴Center of Research and Strategic Studies, Lebanese French University, Erbil, Iraq, ⁵Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Iraq, ⁶Institute of Human Genetics, Jena University Hospital, Jena, Germany, ⁷Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Long noncoding RNAs (lncRNAs) are a class of noncoding transcripts characterized with more than 200 nucleotides of length. Unlike their names, some short open reading frames are recognized for them encoding small proteins. lncRNAs are found to play regulatory roles in essential cellular processes such as cell growth and apoptosis. Therefore, an increasing number of lncRNAs are identified with dysregulation in a wide variety of human cancers. SNHG7 is an lncRNA with upregulation in cancer cells and tissues. It is frequently reported with potency of promoting malignant cell behaviors in vitro and in vivo. Like oncogenic/tumor suppressor lncRNAs, SNHG7 is found to exert its tumorigenic functions through interaction with other biological substances. These include sponging target miRNAs (various numbers are identified), regulation of several signaling pathways, transcription factors, and effector proteins. Importantly, clinical studies demonstrate association between high SNHG7 expression and clinico-pathological features in cancerous patients, worse prognosis, and enhanced chemoresistance. In this review, we summarize recent studies in three eras of cell, animal, and human experiments to bold the prognostic, diagnostic, and therapeutic potentials.

Keywords: SNHG7, non-coding RNA, lncRNA, cancer, biomarker

INTRODUCTION

Initially based on the central dogma of molecular biology lasting for decades, sequential flow of cell genetic information was defined through RNAs, which encoded proteins, and so messenger RNA (mRNA) were considered mediators of template DNA and downstream proteins (Crick, 1970). However, exceptions were gradually made, and RNAs that did not directly encode any protein or polypeptide were identified. Transfer RNAs (tRNA), ribosomal RNAs (rRNAs), and small nuclear and nucleolar RNAs (snRNAs and snoRNAs, respectively) were recognized as groups of non-protein-coding RNAs (ncRNAs) with functions in the translation of coding mRNAs and modification or processing of other RNAs (Hombach and Kretz, 2016). Nowadays, we know that a minority of large genomes in complex eukaryotic organisms encode protein or polypeptide
strands, and a majority [for instance, 98% in humans (Elgar and Vavouri, 2008)] does not encode for amino acids. This great proportion, formerly called “junk DNA,” however, is mainly [e.g., two thirds of the mammalian genomes (Mattick, 2001)] transcribed to thousands of RNA transcripts, including various types of known ncRNAs that are demonstrated to be involved in critical cellular processes through conducting regulatory functions (Najafi et al., 2022). By employment of high-throughput technologies, such as RNA-seq, identification of novel ncRNAs is accelerated, and new members are being introduced constantly (Taheri et al., 2021). Although the role of ncRNAs is not yet clear, however, their involvement in essential life processes have caused them to be the architects of complexity in eukaryotes (Mattick, 2001). The number of functional ncRNAs are growing, and several show regulatory roles on gene expression.

The size of the transcript is the main discriminating parameter used for classification of ncRNAs. Based on a size limit, ncRNAs are divided in two short and long classes. Micro RNAs (miRNAs), rRNAs, tRNAs, and snRNAs/snoRNAs are several described subclasses of short ncRNAs with a total length shorter than 200 nucleotides (Amin et al., 2019). Among them, miRNAs are studied more broadly compared with others, an increasing number identified in mammalian cells, and also a number are reported with altered expression in various human diseases.

Long noncoding RNAs (lncRNAs) are the second class of ncRNAs with characteristic length of >200 nucleotides. Thousands of lncRNA-related genes have been identified in the human genome and corresponding transcripts reported in large quantities by a large number ranging from 10,000 to 60,000 in human cells (Guttman et al., 2009; Iyer et al., 2015). They have been identified in a wide variety of eukaryotic species, and several show conserved sequences among different organisms suggesting evolution pressure (Ramirez-Colmenero et al., 2020). A number of exclusive properties have made lncRNAs different compared with regular miRNAs. These remarkable differences include characteristic biogenesis, localization, structure, and roles (Quinn and Chang, 2016). Unlike protein-coding RNAs, lncRNAs are mainly transcribed from regulatory and noncoding sequences such as promotors, enhancers, and introns. Furthermore, they could be generated from shared sequences with other transcripts (Al-Tobasei et al., 2016) although some researchers consider lncRNAs as noises or byproducts of transcription (Gao et al., 2020). Unlike their names, some short open reading frames are recognized for them that encode for small proteins (Hartford and Lal, 2020). According to the location of transcription, lncRNAs are classified into intronic and intergenic. Structurally, lncRNAs can be found in linear and circular forms, which are mainly referred to as the former structures; however, circular RNAs also have been found with regulatory functions and roles in pathogenesis of various human cancers (Rahmati et al., 2021; Sayad et al., 2021). LncRNAs show specific expression in cell-, tissue-, and developmental stage-specific manners (Sarropoulos et al., 2019). Their biogenesis is also forced to more strict regulation relative to protein-coding transcripts that, along with their conservation among species, suggests critical regulatory functions for lncRNAs (Dahariya et al., 2019). Several strategies, including ribonuclease P cleavage, processing by ribonucleoproteins, and circularization via backsplicing, play a role in biogenesis of lncRNAs (Dahariya et al., 2019). Same as miRNAs, lncRNAs undergo post-transcriptional modifications on processing such as capping and polyadenylation at 5’ and 3’ ends, respectively, splicing and base modifications (Sarropoulos et al., 2019). They are mainly located at the nucleus exerting their epigenetic and gene expression regulatory functions via altering the histone modifications or transcription control through several mechanisms, including scaffold, signal, guide, and decoy (Zhang et al., 2019a; Dahariya et al., 2019). Through these ways, lncRNAs in interactions with DNA, proteins, and other RNAs, play a role in various biological phenomena, such as cell differentiation and reprogramming, organ development, immune responses, and cell cycle control (Statello et al., 2021).

Accordingly, a set of lncRNAs is found to be deregulated in various human disorders. An association between expression level of these transcripts and pathogenesis in major health conditions confirms critical roles of lncRNAs in essential health-affecting processes. Among an increasing number of pathogenic lncRNAs, a handful, such as XIST, MALAT1, HOTAIR, H19, ANRIL, and MEG3, are the best known and most often found transcripts. Playing a role particularly in cancer development and progression, differentially expressed lncRNAs in cancer tissues are functionally subdivided into two group of oncogenic and tumor suppressors.

Small nucleolar RNA host gene 7 (SNHG7) is among the oncogenic lncRNAs with progressive effects in multiple human cancers although a single study suggests tumor suppressor function for SNHG7 in pituitary adenoma (Xue and Ge, 2020). Its corresponding gene, located on chromosome 9q34.3, encodes a 2157-base-pair-long transcript. SNHG7 was reported for the first time in 2013 by Chaudhry in X-ray-treated lymphoblastoid cells (Chaudhry, 2013). Rather than regulation of transcription factors, translation, or stability of mRNAs involved in several diseases such as cardiac fibrosis, hepatic fibrosis, and cardiac hypertrophy in addition to helping fracture repair (Chen et al., 2019a; Jing et al., 2019; Yu et al., 2019; Wang et al., 2020a), SNHG7 is found to be overregulated in cancer tissues compared with healthy tissues in a wide variety of human malignancies, including bladder, prostate, gastric, colorectal, and pancreatic cancers (Li et al., 2018a; Zhong et al., 2018a; Cheng et al., 2019a; Han et al., 2019; Zhang et al., 2020a). This upregulation also is demonstrated to accelerate cancer progression. It is shown that SNHG7 is negatively regulated by insulin-like growth factor 1 (IGF1) signaling at the post-transcriptional level through the MAPK pathway to control cell proliferation (Boone et al., 2020). In cell and animal studies, SNHG7 is shown with oncogenic roles in accordance with clinicopathological features and also diagnostic and prognostic values in cancerous patients. In this review, we have gathered recent findings on the oncogenic roles of this lncRNA in three levels of cell, animal, and human studies with a focus on clinical results predicting SNHG7 as a novel biomarker for different types of human cancers.
Cell Line Studies

Through study of SNHG7 knockdown or overexpression in cancer cell lines, it is demonstrated that expression of this oncogenic lncRNA promotes malignant features of the cells in vitro. This universal finding, although opposite effects have been described for SNHG7 at least in two distinct experiments (Pei et al., 2020; Huang et al., 2020), is reported for a broad spectrum of cancer cell types, such as breast, colorectal, bladder, gastric, liver, etc. Proliferation and colony formation experiments have unveiled increased cell and colony numbers in cancer cells in response to SNHG7 simulated excess expression compared with baseline conditions. Accordingly, reduced apoptosis consistent with elevated tumor cell growth hypothesizes the role of this lncRNA in cancer progression. Migratory and invasive potentials of cancer cells also show enhancement in Transwell and Matrigel assays, respectively. Confering chemoresistance or desensitization has been concluded from cellular studies in which increased sensitivity of cancer cells to conventional chemotherapy agents and/or radiotherapy is seen on SNHG7 knockdown. For example, in two distinct experiments, enhanced sensitivity of breast cancer cells to Adriamycin and Trastuzumab is shown when SNHG7 is silenced or its target sponged miRNA (miR-34a or miR-186, respectively) is overexpressed (Li et al., 2020a; Zhang et al., 2020b). Knockdown studies employing RNA silencing confirm the overexpression experiment results by reversing the SNHG7 impacts on malignant cells behaviors. Via making a network, lncRNAs are known to affect expression of a specific target miRNA. Dual luciferase reporter and RNA immunoprecipitation (RIP) assays confirm the association between SNHG7 and target miRNA consistent with bioinformatics predictions. These interactions seem to be conducted via complementary sequences as binding sites on miRNA for SNHG7. This regulatory effect is mainly repressive, and expression levels in quantitative real-time polymerase chain reaction (qRT-PCR) reveal a negative correlation between both. It is hypothesized that through downregulation of the target miRNA, SNHG7 as a competing endogenous RNA (ceRNA) or sponger exerts its regulatory impacts on downstream transcription factors playing a role in some signaling pathways (Figure 1). Activation of an oncogenic signaling pathway demonstrates why these lncRNAs are considered to have tumor promoting potentials. A handful of evidence on the acceleration of the cell cycle in response to SNHG7 overexpression or arrest in a phase under knockdown conditions suggests indirect enhancing influences of this lncRNA on cell proliferation and differentiation, which consequently, leads to cancer progression. For instance, She et al. (2018) find that SNHG7 upregulates the Fas apoptotic inhibitory molecule 2 (FAIM2) through sponging miR-193b in non-small cell lung cancer (NSCLC) cells. In silico investigations demonstrate binding sites for miR-193b on the SNHG7 sequence. FAIM2 is a membrane protein; shows antiapoptotic activity; is upregulated in several cancers; and is already known to promote tumor cell proliferation, migration,
and invasion in lung cancer cells (She et al., 2016). Repression of proapoptotic proteins, such as Bax, and SIRT1-associated pyroptosis also benefits reduced tumor cell death (Xu et al., 2019; Chen et al., 2020a). Thus, it is not surprising to see repressed apoptosis frequently reported on SNHG7 overexpression, which means steady growth of cancer cells. Enhanced glycolysis through upregulation of lactate dehydrogenase A (LDHA) in the tumor microenvironment is another finding on SNHG7 overexpression, which can help the cancer cell economy (Zhang et al., 2019b; Pei et al., 2021). SNHG7 also causes arrest in the G1/G0 phase of the cell cycle (Wang et al., 2017a; Xu et al., 2018); regulates signaling pathways, such as Wnt/β-Catenin and AKT/mTOR pathways; and represses tumor suppressors, such as P15 and P16 (Wang et al., 2017b; Li et al., 2020b; Chi et al., 2020; Du et al., 2020). Furthermore, an elevated neovascularization rate following SNHG7 overexpression is consistent with tumor progression conditions (Zhang et al., 2019b; Pei et al., 2021). SNHG7 also causes arrest in the G1/G0 phase of the cell cycle (Wang et al., 2017a; Xu et al., 2018); regulates signaling pathways, such as Wnt/β-Catenin and AKT/mTOR pathways; and represses tumor suppressors, such as P15 and P16 (Wang et al., 2017b; Li et al., 2020b; Chi et al., 2020; Du et al., 2020). SNHG7 knockdown suppresses tumor growth via decreasing tumor size in vivo, whereas faster tumor growth is reported for SNHG7-overexpressing implanted cells compared with control animals. This effect is reported for SNHG7 silencing in various cancer models (Table 1). Decreased tumor metastasis or repression of some carcinogenic signaling pathways, such as the Notch pathway, is also reported in other animal studies (Sun et al., 2019). For instance, several studies assess the role of SNHG7 knockdown on hepatocellular carcinoma (HCC) growth in xenograft mice (Yang et al., 2019; Yao et al., 2019; Xie et al., 2020; Zhao et al., 2021). Yang et al. (2019) demonstrate lower tumor volume and percentage of Ki-67-stained HCCLM3 cells.

**Animal Studies**

Xenograft animal experiments with inoculation of cancer cells into nude mice try to simulate the cancer conditions in an animal model. BALB/C nude mice are used to evaluate the effect of lncRNA upregulation and/or downregulation in vivo. Cancer cells transfected with a vector expressing small heterogenous RNA (shRNA) for overexpression or small interfering RNA for knockdown of the lncRNA along with a vector expressing a control scrambled sequence are injected into the flank of nude mice to establish the xenograft mouse model. Size and volume of the tumor created in the mice is then calculated to compare the tumor growth after sacrificing the animals. Using immunohistochemistry for detection of Ki-67 as a proliferation marker in excised tumor tissues, it is feasible to assess the implanted tumor cell proliferation. Xenograft animal experiments in a number of studies demonstrate that SNHG7 knockdown suppresses tumor growth via decreasing tumor size in vivo, whereas faster tumor growth is reported for SNHG7-overexpressing implanted cells compared with control animals. This effect is reported for SNHG7 silencing in various cancer models (Table 1). Decreased tumor metastasis or repression of some carcinogenic signaling pathways, such as the Notch pathway, is also reported in other animal studies (Sun et al., 2019). For instance, several studies assess the role of SNHG7 knockdown on hepatocellular carcinoma (HCC) growth in xenograft mice (Yang et al., 2019; Yao et al., 2019; Xie et al., 2020; Zhao et al., 2021). Yang et al. (2019) demonstrate lower tumor volume and percentage of Ki-67-stained HCCLM3 cells.

---

**FIGURE 2** | Signaling pathways and cellular processes are affected by SNHG7 to enhance tumor progression in cancer cells. Through sponging miR-34a, SNHG7 activates several signaling pathways, such as Notch-1 and PI3K/Akt/mTOR in breast and colorectal cancer, respectively. Other pathways, such as Wnt/β-catenin and K-ras/ERK/cyclinD1, are also affected via other target miRNAs. The effect of SNHG7 on enhancement of glycolysis through upregulation of lactate dehydrogenase A (LDHA) has beneficial effects for cancer cells metabolism.
and less lung metastasis of HCCLM3 cells in an SNHG7 knockdown mice group compared with the control group. Additionally, Yao et al. (2019) show that the expression of the metastasis-associated protein matrix metalloproteinase-9 (MMP-9) is increased in SNHG7-overexpressing HepG2 implanted cells, suggesting a mechanism for enhancing the effect of SNHG7 on tumor metastasis. Collectively, promoted tumor growth on SNHG7 overexpression and/or suppressed tumor proliferation on SNHG7 knockdown is reported in a body of studies. These results, along with cellular findings, confirm the oncogenic role of SNHG7, and the knockdown achievements may suggest therapeutic potentials for anticancer therapies.

### Human Studies

Consistent with cellular findings, enormous expression assessments using qRT-PCR analysis demonstrate elevated SNHG7 expression in tissues retrieved from cancerous patients compared with healthy adjacent tissues. Increased SNHG7 tissue expression is frequently found to be associated with worse clinicopathological features, which are used in clinical classification and staging of human malignancies. Importantly, patients with more advanced clinicopathological characteristics are predicted to have worse prognosis and severe outcomes. These include larger tumor size, more advanced clinical stage, poor histologic grade, deeper tumor invasion, and lymph node metastasis in accordance with high SNHG7 expression in the affected patients (Zeng et al., 2019; Pang et al., 2020; Zhu et al., 2021). This value is also shown in malignancies with broad and different features and in meta-analyses pooling data of tens of studies (Yu et al., 2021a; Yi et al., 2021; Yu et al., 2021b). For example, in acute myeloid leukemia (AML), an association between SNHG7 and SNHG12 IncRNAs and specific clinical/molecular features, including white blood cell (WBC) counts and mutations in IDH1, RUNX1, and NPM1 genes, shows high value of SNHG7 in correlation with extensive features (Shi et al., 2020). These demonstrations suggest that elevated SNHG7 expression predicts poor clinicopathological characteristics. In other words, high SNHG7 expression can predict worse outcomes following poor clinicopathological determinants. In accordance with clinicopathological findings, SNHG7 also shows correlation with prognostic parameters. Survival analysis using a Kaplan–Meier curve indicates shorter survival time in overall survival (OS) and disease-free survival (DFS) for patients with high SNHG7 expression relative to those with low levels. This finding is reported for various human cancers, for which survival analysis is conducted (Table 2). For example, in three distinct studies that reported survival analyses in HCC patients, among a total of 150 patients, poorer OS time was reported separately for the patients with elevated tissue SNHG7 expression in comparison to those with low levels (Yang et al., 2019; Zhao et al., 2021; Yao et al., 2019). Additionally, recurrence is predicted to happen in shorter durations and higher rates among patients with high SNHG7 expression (Zhang et al., 2020c).

### Table 1: Effects of SNHG7 on tumor growth and metastasis in animal studies.

| Cancer type                     | Animal models                                                                 | Function                                                                 | References (s) |
|---------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------|
| Pancreatic cancer               | Nude mice                                                                     | $\Delta$ SNHG7: ↓ tumor growth                                       | Jian and Fan, (2021) |
|                                 | Female BALB/C nude mice                                                      | $\Delta$ SNHG7: ↓ tumor growth                                       | Cheng et al. (2019b) |
| Breast cancer                   | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Zhang et al. (2020b) |
|                                 | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Li et al. (2020d) |
|                                 | BALB/c athymic nude mice                                                     | $\Delta$ SNHG7: ↓ tumor growth, EMT, and Notch-1 pathway             | Sun et al. (2019) |
| Colorectal cancer               | Nude mice                                                                     | $\Delta$ SNHG7: ↓ tumor growth                                       | Li et al. (2018b) |
| Lung cancer (non-small cell lung cancer; NSCLC) | Nude mice | $\Delta$ SNHG7: ↓ tumor growth | Li et al. (2020b) |
|                                 | Athymic nude mice                                                            | $\Delta$ SNHG7: ↓ tumor growth                                       | Wang et al. (2020b) |
|                                 | Nude mice                                                                     | $\Delta$ SNHG7: ↓ tumor growth                                       | She et al. (2018) |
| Liver cancer (hepatocellular carcinoma; HCC) | BALB/c male nude mice            | $\Delta$ SNHG7: ↓ tumor growth                                       | Zhao et al. (2021) |
|                                 | BALB/c male nude mice                                                        | $\Delta$ SNHG7: ↓ tumor growth                                       | Xie et al. (2020) |
|                                 | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth, and metastasis                       | Yang et al. (2019) |
| Gastric cancer                  | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Yao et al. (2019) |
| Bladder cancer                  | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Wang et al. (2017b) |
| Pituitary adenocarcinoma         | Nude mice                                                                     | $\Delta$ SNHG7: ↓ tumor growth                                       | Wang et al. (2020c) |
| Neuroblastoma                   | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Yue et al. (2021) |
| Glioma                          | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Jia et al. (2020) |
| Thyroid                         | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Du et al. (2020) |
|                                 |                                                                                | $\Delta$ SNHG7: ↓ tumor growth, and 131I resistance                  | Chen et al. (2021) |
| Glioblastoma                    | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth, and metastasis                       | Ren et al. (2018) |
| Ovarian cancer                  | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Bai et al. (2020) |
| Cervical cancer                 | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth                                       | Zhao et al. (2020) |
| Prostate cancer                 | BALB/c nude mice                                                             | $\Delta$ SNHG7: ↓ tumor growth, and cell cycle arrest                | Qi et al. (2018) |

Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 January 2022 | Volume 9 | Article 809345
TABLE 2 | Clinical prognostic importance of SNHG7 in human cancers.

| Cancer type                                      | Clinical samples                              | Expression change in tumor tissues compared to normal tissues | Associated clinical features                                                                 | Kaplan–Meier analysis                                                                 | Multivariate cox regression | References (s)                                                                 |
|--------------------------------------------------|-----------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------------------------|
| Lung cancer                                      | 36 cancerous patient tissues and matched NATs | Upregulated                                                 | —                                                                                             | Patients with elevated expression levels of SNHG7 demonstrated decreased OS rate compared to those with lower levels | —                            | Li et al. (2020b)                                                                |
|                                                  | 30 cancerous patient tissues and matched NATs | Upregulated                                                 | —                                                                                             | —                                                                                       | —                            | Wang et al. (2020b)                                                             |
| Esophageal cancer                                | 40 cancerous patient tissues and matched NATs | Upregulated                                                 | —                                                                                             | —                                                                                       | —                            | Wang et al. (2021)                                                              |
| Liver (hepatocellular carcinoma; HCC)            | 30 cancerous patient tissues and matched NATs | Upregulated                                                 | Tumor size, TNM grade, and Distant metastasis                                               | Log-rank test demonstrated that patients with high SNHG7 expression had poorer OS.     | —                            | Zhao et al. (2021)                                                              |
|                                                  | 25 cancerous patient tissues and matched NATs | Upregulated                                                 | —                                                                                             | —                                                                                       | —                            | Chen et al. (2020a)                                                            |
|                                                  | 80 cancerous patient tissues and matched NATs | Upregulated                                                 | Tumor stages, tumor grade, and vascular invasion                                           | Patients with high SNHG7 expression levels had poor OS.                                | —                            | Yang et al. (2019)                                                             |
|                                                  | 40 cancerous patient tissues and matched NATs | Upregulated                                                 | TNM stage, and tumor metastasis                                                            | Elevated SNHG7 expression was markedly associated with poor OS in hepatic carcinoma patients | —                            | Yao et al. (2019)                                                              |
|                                                  | 100 cancerous patient tissues and matched NATs | Upregulated                                                 | Tumor number, lymph node metastasis, and clinical stage                                    | Patients with high SNHG7 expression demonstrated worse OS and PFS relative to those with low levels | SNHG7 expression acts as an independent prognostic factor for OS and occurrence in HCC patients | Shen et al. (2020)                                                            |
| Synchronous colorectal liver metastasis (SCLM)   | 96 SCLM patients                              | Upregulated                                                 | Differentiation of primary tumor, invasion depth of primary focus, lymph node metastases, number of liver metastases, and liver metastasis grade | Patients with high SNHG7 expression levels had poor OS.                                | SNHG7 expression acts as an independent prognostic factor for OS and occurrence in SCLM patients | Zhang et al. (2020c)                                                          |
| Pancreatic cancer                                | 50 cancerous patient tissues and matched NATs | Upregulated                                                 | tumor size, TNM stage, lymph node metastasis, and distant metastasis                        | Patients with elevated expression levels of SNHG7 demonstrated decreased survival rate relative to those with lower levels | Patients with high SNHG7 expression levels had poor OS. | Jian and Fan, (2021)                                                          |
|                                                  | 40 cancerous patient tissues and matched NATs | Upregulated                                                 | —                                                                                             | —                                                                                       | —                            | Cheng et al. (2019b)                                                            |
| Breast cancer                                    | 43 cancerous patient tissues                  | Upregulated                                                 | Tumor size, TNM stage, and Ki-67 index                                                       | Patients with high SNHG7 levels had lower DFS compared to those with lower levels      | —                            | Li et al. (2020a)                                                              |
|                                                  | 50 cancerous patient tissues and matched NATs | Upregulated                                                 | Pathological stage, and lymph node metastasis                                               | —                                                                                       | —                            | Li et al. (2020d)                                                              |
|                                                  | 837 cancerous patient tissues and matched NATs| Upregulated                                                 | —                                                                                             | High SNHG7 was associated with decreased survival in breast cancer patients             | —                            | Zhang et al. (2019b)                                                            |
|                                                  | 72 cancerous patient tissues and matched NATs | Upregulated                                                 | Clinical Stage, lymph node and distant metastasis                                           | High SNHG7 was correlated with shorter survival time in breast cancer patients           | —                            | Luo et al. (2018)                                                              |

(Continued on following page)
### TABLE 2 | (Continued) Clinical prognostic importance of SNHG7 in human cancers.

| Cancer type                     | Clinical samples                                             | Expression change in tumor tissues compared to normal tissues | Associated clinical features                                                                 | Kaplan–Meier analysis                                      | Multivariate cox regression | References (s)                                                                 |
|---------------------------------|--------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------|--------------------------------------------------------------------------------|
| Gastric cancer                  | 30 cancerous patient tissues and 30 healthy tissues          | Upregulated                                                | —                                                                                             | —                                                          | —                          | Pei et al. (2021)                                                             |
|                                 | 36 cancerous patient tissues and matched NATs               | Upregulated                                                | —                                                                                             | —                                                          | —                          | Zhao and Liu, (2021)                                                        |
|                                 | 162 cancerous patient tissues and matched NATs              | Upregulated                                                | TNM stage, depth of invasion, lymph node and distant metastasis                               | Patients with high SNHG7 levels showed lower OS compared to those with high SNHG7 expression | SNHG7 acts as an independent factor for poor OS in patients with gastric cancer | Zhang et al. (2020a)                                                      |
| Bladder cancer                  | 60 cancerous patient tissues and matched NATs               | Upregulated                                                | Clinical stage                                                                                 | Patients with high SNHG7 levels showed unfavorable prognosis | —                          | Wang et al. (2020c)                                                          |
|                                 | 92 cancerous patient tissues and matched NATs               | Upregulated                                                | Tumor range, lymph nodes, and pathological stage                                                | Patients with high SNHG7 levels had poor OS compared to those with low levels | —                          | Chen et al. (2019b)                                                         |
| Pituitary adenocarcinoma         | 30 cancerous patient tissues and matched NATs               | Upregulated                                                | —                                                                                             | Patients with high SNHG7 levels showed unfavorable prognosis compared to those with low levels | —                          | Yue et al. (2021)                                                           |
| Glioma                          | 30 cancerous patient tissues and matched NATs               | Upregulated                                                | —                                                                                             | —                                                          | —                          | Cheng et al. (2020)                                                         |
|                                 | 20 and 33 cancerous patient tissues and matched NATs        | Upregulated                                                | Tumor grade                                                                                   | —                                                          | —                          | (Du et al., 2020; Deng et al., 2021)                                        |
| Glioblastoma                    | 53 cancerous patient tissues and matched NATs               | Upregulated                                                | WHO Grade                                                                                     | --                                                         | --                         | Chen et al. (2020b)                                                         |
|                                 | 53 cancerous patient tissues and matched NATs               | Upregulated                                                | —                                                                                             | Patients with high SNHG7 levels had poor survival rates compared to those with low levels | —                          | Ren et al. (2018)                                                           |
| Neuroblastoma                   | 45 cancerous patient tissues and matched NATs               | Upregulated                                                | Clinical stage                                                                                 | Patients with low SNHG7 levels demonstrated longer OS compared to those with high levels | —                          | Jia et al. (2020)                                                           |
|                                 | 92 cancerous patient tissues and matched NATs               | Upregulated                                                | Lymph node metastasis, INSS stage, and optic nerve invasion                                  | Patients with high SNHG7 levels had poorer prognosis compared to those with high levels | —                          | Chi et al. (2019)                                                           |
| Thyroid cancer                  | 56 normal samples and 578 tumor samples                     | Upregulated                                                | Pathology stage                                                                                | Patients with high SNHG7 levels shorter DFS times compared with those with low levels | —                          | Chen et al. (2019c)                                                         |
| Cervical cancer                 | 45 cancerous patient tissues and matched NATs               | Upregulated                                                | Tumor Size, FIGO Stage, and lymph-Node Metastasis                                             | Patients with high SNHG7 levels demonstrated poorer OS compared to those with low levels | —                          | Zhao et al. (2020)                                                          |
|                                 | 60 cancerous patient tissues and matched NATs               | Upregulated                                                | TNM stage, lymph node metastasis, and depth of tumor invasion                                 | Patients with high SNHG7 levels demonstrated poorer OS compared to those with low levels | SNHG7 acts as an independent factor for poor OS in patients with gastric cancer | Zeng et al. (2019)                                                        |
Cox regression analyses confirm the predictive value of SNHG7 as an independent prognostic factor among cancerous patients. This is particularly reported in several district experiments on human malignancies such as gastric cancer, cervical cancer, HCC, and liver metastasis following hepatectomy in CRC patients (Table 2) (Zeng et al., 2019; Zhang et al., 2020a; Zhang et al., 2020c; Shen et al., 2020). As for diagnostic values, an area under curve (AUC) of 0.84 in the receiver operating characteristic (ROC) curve is reported for SNHG7 in CRC patients (Hu et al., 2019). Importantly, SNHG7 is demonstrated as a potential therapeutical target as it is identified in several studies to lead to enhanced chemoresistance to several anticancer agents such as Cisplatin, Trastuzumab, and Folfilrinox in the cancer cells (Chen et al., 2019d; Li et al., 2020a; Zhang et al., 2020b; Dai et al., 2020; Cheng et al., 2021; Pei et al., 2021). Also, metformin with anticancer properties is found to exert its effects in sensitization to Paclitaxel via regulation of SNHG7/miR-3127-5p-mediated autophagy in ovarian cancer cells (Yu et al., 2020). In another study, metformin is demonstrated to suppress growth of hypopharyngeal cancer cells through epigenetic silencing of SNHG7 (Wu et al., 2019). Taken together, human studies suggest SNHG7 lncRNA with promising diagnostic, prognostic, and therapeutic potentials in various types of cancer.

**DISCUSSION**

LncRNAs are a group of ncRNA transcripts defined with a length of >200 nucleotides. Although not elucidated, however, a number of regulatory functions are described for lncRNAs. They are involved in controlling several biological processes, such as cell cycle and proliferation. Accordingly, dysregulation of lncRNAs is identified in a number of human malignancies, suggesting diagnostic and therapeutic potentials. SNHG7 is an lncRNA that has been studied as an oncogenic transcript in a handful of cellular and animal experiments. It is upregulated in cancer cells and tissues retrieved from cancerous patients. SNHG7 is shown to be predominantly localized in the cytoplasm, where it serves as a ceRNA to sponge miRNAs and control expression of downstream targets (Hu et al., 2019). In vitro experiments frequently demonstrate a promoted malignant phenotype of cancer cells on SNHG7 overexpression, whereas its knockdown reverses tumor cell proliferation, migration, and invasion and enhances apoptosis. These regulatory effects are thought to be conducted through an axis of action affecting translation and stability of several transcription factors and signaling pathways mediated by sponging target miRNAs. Not a single one, but plenty of miRNAs are identified to be sponged by SNHG7 (see Table 3). Xenograft animal studies confirm the
### TABLE 3 | An overview to the oncogenic influences of SNHG7 in cell studies of different types of cancer.

| Cancer type | Targets/Regulators and signaling pathways | Assessed cell lines | Function | References(s) |
|-------------|------------------------------------------|---------------------|----------|---------------|
| Lung cancer | miR-485-5p/WLS axis                       | H1650, H1975, A549 and H1299 | ↑↑ SNHG7: ↑ tumor cell proliferation, ↑ migration, and ↓ invasion | Li et al. (2020c) |
|             | miR-181a-5p/MTOR axis                     | A549, and NCI-H1299 | ↑↑ SNHG7: ↑ tumor cell proliferation, ↑ migration, and ↓ invasion | Li et al. (2020b) |
|             | miR-181a-5p/FAIM2 axis                    | BEAS-2B, H125, 95D, and A549 | ↑↑ SNHG7: ↑↑ FAIM2 | She et al. (2018) |
|             | miR-181a-5p/E2F7 Axis                     | NCI-H520, SPC-A1, H-23, and BEAS-2B | ↑↑ SNHG7: ↑↑ tumor cell viability, ↑ colony formation, ↑ migration, ↑ invasion and ↓ apoptosis | Wang et al. (2020b) |
|             | miR-349a/TGIF2 axis                       | BEAS-2B, BA59, A549, and H1299 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑ migration, ↓ invasion, and ↓ EMT | Pang et al. (2020) |
|             | FAIM2                                     | BEAS-2B, H125, 95D, and A594 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑ migration, ↓ invasion and ↓ apoptosis | She et al. (2016) |
|             | miR-34a-5p                               | NSCLC cells | ↑↑ SNHG7: ↑↑ tumor cell proliferation | Chai et al. (2021) |
| Esophageal cancer | miR-625/SNHG7 axis                      | TE1, EC109, TE13, and YES2 | ↑↑ SNHG7: ↑ tumor cell proliferation, ↑ migration, and ↓ invasion | Wang et al. (2021) |
|             | —                                        | HEEC, Eca109, EC9706, TE-10, and TE-11 | ↑↑ SNHG7: ↑ tumor cell proliferation, ↑ cell cycle arrest, and ↓ apoptosis | Xu et al. (2018) |
| Nasopharyngeal cancer | miR-514a-5p/ELAVL1 axis                 | NP69, CNE1, CNE2, C666-1 and HNE1 | ↑ SNHG7: ↑ tumor cell proliferation, and ↑ colony formation | Hu et al. (2020) |
|             | miR-140-5p/GLI3 axis                     | CNE1, HONE1, C666-1, and CNE2 | ↑ SNHG7: ↑ tumor cell proliferation, ↓ drug resistance, and ↓ apoptosis | Dai et al. (2020) |
| Liver cancer (hepatocellular carcinoma; HCC) | miR-122-5p/FOXO2 axis                    | SNU449, Hep3B, and THLE-2 | ↑↑ SNHG7: ↑ tumor cell proliferation, ↑ migration, ↑ invasion, and ↓ EMT | Zhao et al. (2021) |
|             | miR-34a/SIRT1 axis                       | THLE-3, HEK-293, HepG2, and SK-hep-1 | ↑↑ SNHG7: ↑↑ NLRP3-dependent pyroptosis | Chen et al. (2020a) |
|             | miR-9-5p/CNNM1 axis                      | THLE-3, BEL-7404, HCCLM3, Hep3B and HepG2 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑ colony formation, and ↑ apoptosis | Xie et al. (2020) |
|             | miR-122-5p/PARL4 axis                    | Huh7, Hep3B, HCCLM3, and MHCC97H | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ colony formation, and ↓ EMT | Yang et al. (2019) |
|             | miR-425/Wnt/b-catenin/ EMT pathway       | HepG32, and HCC-LM3 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ colony formation, and ↓ invasion | Yao et al. (2019) |
| Pancreatic cancer | miR-146b-5p/Robo1 axis                  | PANc-1, SW 1990, BxPC-3 and AsPC-1 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, ↑↑ invasion, and ↓ EMT | Jian and Fan, (2021) |
|             | miR-342-3p/D4 axis                      | HPD66-C7, HEK293T, AsPC-1, BxPC-3, SW 1990, PANc-1, and PaCa-2 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, and ↓ EMT | Cheng et al. (2019b) |
|             | Notch1/Jagged1/Hes-1 Signaling Pathway   | PANc-1, and AsPC-1 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, and ↓ EMT | Cheng et al. (2021) |
| Breast cancer | miR-15a                                   | MCF7, and T47D | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, and ↓ invasion | Li et al. (2020d) |
|             | miR-34a                                   | MCF-7, and MDA-MB-231 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, and ↓ invasion | Li et al. (2020a) |
|             | miR-186                                   | SK-BR-3, and AU565 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, and ↓ invasion | Zhang et al. (2020b) |
|             | miR-34a-5p/LDH (Glycolysis) axis         | MCF10A, MDA-MB-436, HS578T, SKBR3, MDA-MB-231, and MCF-7 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ glycolysis | Gao and Zhou, (2019) |
|             | miR-381                                   | MCF10A, MDA-MB-436, HS578T, SKBR3, MDA-MB-231, and MCF-7 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ glycolysis | Sun et al. (2019) |
|             | miR-34a/Notch-1 pathway                  | MCF10A, MDA-MB-436, HS578T, SKBR3, MDA-MB-231, and MCF-7 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑↑ migration, and ↓ invasion | Luo et al. (2018) |
| Colorectal cancer | miR-23a-3p/CXCL12 axis                  | SW480, LoVo, RKO, and HCT116 | ↑↑ SNHG7: ↑↑ tumor cell viability, ↑ proliferation, and ↓ migration | Liu et al. (2020) |
|             | miR-193b-K-ras/ERK/cyclinD1 axis         | — | ↑↑ SNHG7: ↑↑ tumor cell proliferation, and ↓ invasion | Liu et al. (2019) |
|             | miR-34a/GALNT1/PKIk/Akt/mTOR pathway     | FHc, caco2, SW480, SW620, Hct116, and LoVo | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑ migration, ↓ vascuogenic mimiciy, ↑ cell cycle progression, and ↓ apoptosis | Li et al. (2018b) |
|             | miR-216b/GALNT1 axis                     | FHc, SW480, SW620, LOVO, and HCT-116 | ↑↑ SNHG7: ↑↑ tumor cell proliferation, ↑ migration, ↓ vascuogenic mimiciy, ↑ cell cycle progression, and ↓ apoptosis | Shan et al. (2018) |
### TABLE 3 | (Continued) An overview to the oncogenic influences of SNHG7 in cell studies of different types of cancer.

| Cancer type | Targets/Regulators and signaling pathways | Assessed cell lines | Function | References(s) |
|-------------|-----------------------------------------|---------------------|----------|---------------|
| Gastric cancer | miR-34a/LDH (Glycolysis) axis | HGC27, and AGS | Δ SNHG7: ↑ tumor cell viability and ↓ chemosensitivity of cancer cells to cisplatin | Pei et al. (2021) |
| | miR-485-5p | HS746T, HGC-27, SNU-1, AGS, and GES-1 | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, and ↓ invasion | Zhao and Liu, (2021) |
| | miR-34a/Snail/EMT axis | GE-5, MKN-45, SGC-7901, and N87 | Δ SNHG7: ↑ tumor cell migration, and ↓ invasion | Zhang et al. (2020a) |
| | P15 and P16 | BGC823, MGC803, SGC7901, N87, and AGS | Δ SNHG7: ↑ tumor cell migration, ↓ colony formation, and ↓ apoptosis, and ↓ cell cycle arrest | Wang et al. (2017b) |
| Bladder cancer | miR-2682-5p/ELK1/Src/FAK signaling pathway | T24, SW780, J82, UM-UC-3, 5637, and SE780 | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ apoptosis | Wang et al. (2020c) |
| | Bax, p21, and E-cadherin | SW780, T24, UMUC, and 5637 | Δ SNHG7: ↑ tumor cell proliferation, ↓ invasion, and ↓ apoptosis, and ↑ expression of Bax, p21 and E-cadherin proteins | Xu et al. (2019) |
| | Wnt/β-catenin pathway | SV-HUC-1, T24, 5637, 253 J, TCC, J82, and EJ | Δ SNHG7: ↑ tumor cell proliferation, ↓ colony formation, ↓ migration, and ↓ cell cycle arrest | Chen et al. (2019b) |
| | — | SV-HUC-1, T24, J82, and SW780 | Δ SNHG7: ↑ tumor cell proliferation, ↓ invasion, ↓ EMT, and ↓ apoptosis | Zhong et al. (2019a) |
| Pituitary adenocarcinoma | miR-449a | GH1, RC-4B/C, GH3 and MMQ | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, and ↓ invasion | Yue et al. (2021) |
| Glioma | miR-342-3p/AKT2 axis | A172, U87, U251, and SHG44 | ↑↑ SNHG7: ↑ tumor cell proliferation, ↓ migration, and ↓ invasion | Deng et al. (2021) |
| | miR-506-5p/CTNNB1 axis | NHA, U87, U251, SHG44, and A172 | Δ SNHG7: ↑ tumor cell proliferation, ↓ colony formation, and ↓ apoptosis | Chen et al. (2017a) |
| | miR-138-5p/EZH2 axis | LN229, A172, U251, and U87 | Δ SNHG7: ↑ tumor cell proliferation | Du et al. (2020) |
| Glioblastoma (GBM) | miR-449b-5p/MYCN axis | T24, SW780, J82, UM-UC-3, 5637, and SE780 | Δ SNHG7: ↑ GBM cell viability, ↓ migration, and ↓ invasion | Yuen et al. (2021) |
| | miR-5095/Wnt/b-catenin pathway | HEB, A172, U87, T98G, and SHG44 | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ apoptosis | Ren et al. (2018) |
| Neuroblastoma | miR-323a-5p and miR-342-5p/CCND1 axis | SH-SY5Y, SK-N-SH, NB-1, SK-N-AS, and HuVEC | Δ SNHG7: ↑ tumor cell migration, ↓ invasion, and ↑ glycolysis | Jia et al. (2020) |
| | miR-653-5p/STAT2 axis | SH-SY5Y, SK-N-SH, NB-1, SK-N-AS, and HuVEC | Δ SNHG7: ↑ tumor cell migration, ↓ invasion, and ↓ EMT, ↓ cell cycle arrest, and ↓ apoptosis | Chi et al. (2019) |
| Ovarian cancer | EZH2/KLF2 axis | OC A2780, OCC1, H8710 and SK-OV3 | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ EMT | Bai et al. (2020) |
| Melanoma | six human UM cell lines | E2H2 | Δ SNHG7: ↑ tumor cell proliferation, ↓ cell cycle arrest, and ↓ apoptosis | Huang et al. (2020) |
| Cervical cancer | DKK1/Wnt/β-catenin axis | H8, C-33A, CaSkI, SiHa, and HeLa | Δ SNHG7: ↑ tumor cell proliferation, ↓ colony formation, and ↓ apoptosis | Qi et al. (2018) |
| | miR-485-5p/UUND axis | Ect1/E6E7, HEK-293T, Hela, SiHa, C-33A and HT-3 | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ EMT, and ↓ apoptosis | Ren et al. (2018) |
| | — | HeLa, and C-33A | Δ SNHG7: ↑ tumor cell proliferation, and ↓ invasion | Zeng et al. (2019) |
| Thyroid cancer | miR-449a/ACSL1 axis | Nthy-ori-3-1, FT1C33, TPC1, BCPAP, and B505C | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, and ↓ apoptosis | Guo et al. (2020) |
| | — | CAL62, and SW579 | Δ SNHG7: ↑ tumor cell proliferation, and ↓ cell cycle | Chen et al. (2019c) |
| | BDNF | K1, TPC-1, SW579, and Nthy-ori 3-1 | Δ SNHG7: ↑ tumor cell proliferation, ↓ colony formation, and ↓ apoptosis | Wang et al. (2019) |
| | miR-9-5p/DPP4 axis | TPC-1, and B-CPAP | Δ SNHG7: ↑ tumor cell proliferation, and ↓ [3H] resistance | Chen et al. (2021) |
| Prostate cancer | miR-324-3p/WNT2B axis | RWPE, LNCaP, PC-3, and Du-145 | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, and ↓ EMT | Han et al. (2019) |
| | miR-503/cyclin D1 axis | WPMY1, LNCaP, VCaP, 22RV1, DU145, and PC3 | Δ SNHG7: ↑ tumor cell proliferation, and ↓ colony formation | Qi et al. (2018) |
| Osteosarcoma | p53/DNMT1 axis | U2OS, HOS, MG-63, and Saos-2 | Δ SNHG7: ↑ tumor cell proliferation, ↓ cell cycle arrest, and ↓ apoptosis | Zhang et al. (2019c) |
| | miR-34a | NFO81.19, MG63, SaOS2, HOS, and 143B | Δ SNHG7: ↑ tumor cell proliferation, ↓ migration, and ↓ EMT | Deng et al. (2018) |
| | miR-34a-5p/RAD9A axis | GSE70415 dataset | Δ SNHG7: ↑ tumor cell proliferation, ↓ invasion, ↓ EMT, and ↓ apoptosis in situ evaluations showed that SNHG7 may enhance cell proliferation and metastasis | Wang et al. (2020d) |

*Δ:* knockdown or silencing, ↓: decrease or repression, ↑: increase or induction, ↑↑: overexpression, EMT: epithelial-to-mesenchymal transition.
oncogenic role of SNHG7 as tumor growth and metastasis of grafted cancer cells are promoted, whereas SNHG7 knockdown represses them (see Table 1). A promoted association between upregulated SNHG7 expression and worse clinicopathological characteristics in cancerous patients, clinical studies support oncogenic features of SNHG7. Eventually, Kaplan–Meier survival and Cox univariate and multivariate analyses suggest SNHG7 as a potential prognostic and diagnostic biomarker for human malignancies. Importantly, knockdown experiences and also the contributing role of SNHG7 in chemoresistance suggest it as a potential therapeutic target, which can benefit the anticancer therapies.

Exosomal lncRNAs show high stability and concentrations and, thus, can be detected in body fluids (Tellez-Gabriel and Heymann, 2019). Regarding changes in expression levels of lncRNAs and their high diagnostic values, this makes them appropriate candidates for diagnosis and prediction of prognosis in human cancers (Qian et al., 2020). Several methodologies, including ultracentrifugation, are used to isolate exosomes and then detect the RNAs within. Although, due to low costs and higher accessibility, qRT-PCR is routinely used. Our study is consistent with the results of the previous study wherein the RNAs were isolated and then detected using qRT-PCR. Although, these results are consistent with previous studies, the application of qRT-PCR restricts the clinical application of commonly used qRT-PCR, requires more time to take the lncRNAs into the clinical setting (Jensen, 2012). Finally, in this study, there is no CRISPR-based genome editing or siRNA-based method approved or tested for suppression of SNHG7.

In conclusion, regarding a considerable number of studies that reveal oncogenic role of SNHG7 in human cancers and its prognostic value, SNHG7 is suggested as a potential cancer biomarker for human malignancies. Further investigations and more time are required for SNHG7 clinical applications in detection, prediction of prognosis, and treatment of human malignancies.

**AUTHOR CONTRIBUTIONS**

SG-F and SN wrote the draft and revised it. MT designed and supervised the study. BH, MH, and HJ collected the data and designed the figures and tables. All the authors read and approved the submitted version.

**REFERENCES**

Al-Tobasei, R., Paneru, B., and Salem, M. (2016). Genome-wide Discovery of Long Non-coding RNAs in Rainbow trout. *PloS One* 11(2), e0148940. doi:10.1371/journal.pone.0148940

Amin, N., McGrath, A., and Chen, Y.-P. P. (2019). Evaluation of Deep Learning in Non-coding RNA Classification. *Nat. Mach. Intell.* 1(5), 246–256. doi:10.1038/s41225-019-0051-2

Bai, Z., Wu, Y., Bai, S., Yan, K., Kang, H., Ma, W., et al. (2020). Long Non-coding RNA SNHG7 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with EZH2 in Ovarian Cancer. *J. Cel Mol Med*. 24(13), 7479–7489. PubMed PMID: 32420885. Epub 05/18. eng. doi:10.1111/jcmm.13573

Boone, D. N., Warburgton, A., Som, S., and Lee, A. V. (2020). SNHG7 Is a lncRNA Oncogene Controlled by Insulin-like Growth Factor Signaling through a Negative Feedback Loop to Tightly Regulate Proliferation. *Sci. Rep.* 10(1), 8583. PubMed PMID: 32444795. Pubmed Central PMCID: PMC7244715. Epub 2020/05/24. eng. doi:10.1038/s41598-020-65109-7

Chai, R., Xu, C., Lu, L., Liu, X., and Ma, Z. (2021). Quercetin Inhibits Proliferation of and Induces Apoptosis in Non-small-cell Lung Carcinoma via the lncRNA SNHG7–miR-34a-5p Pathway. *Immunopharmacology and immunotoxicology* 43(6), 693–703. PubMed PMID: 34448661. Epub 2021/08/28. eng. doi:10.1080/08929973.2021.1966032

Chaudhry, M. (2013). Expression Pattern of Small Nucleolar RNA Host Genes and Long Non-coding RNA in X-Rays-Treated Lymphoblastoid Cells. *Jnu* 14(5), 9099–9110. PubMed PMID: 23698766. doi:10.3390/jims14090999

Chen, K., Abuduwufuer, A., Zhang, H., Luo, H., Suotesiyali, M., and Zou, Y. (2019). SNHG7 Mediates Gelsatin-Resistance in Non-small Cell Lung Cancer by Activating PI3K/AKT Pathway. *Eur. Rev. Med. Pharmacol. Sci.* 23(16), 6935–6943. PubMed PMID: 31486493. Epub 2019/09/06. eng. doi:10.26355/eurrev_201908_18733

Chen, L., Zhu, J., and Zhang, L. J. (2019). Long Non-coding RNA Small Nucleolar RNA Host Gene 7 Is Upregulated and Promotes Cell Proliferation in Thyroid Cancer. *Oncol. Lett.* 18(5), 4726–4734. PubMed PMID: 31611982. Epub 08/27. eng. doi:10.3892/ol.2019.10782

Chen, W., Yu, J., Xie, R., Zhou, T., Xiong, C., Zhang, S., et al. (2021). Roles of the SNHG7/microRNA-9-5p/DDP4 ceRNA Network in the Grown and 1311 R-existance of T-hyroid C-arcinoma C-cells through PI3K/Akt A-citation. *Oncol. Rep.* 45(4), 3. PubMed PMID: 33649840. Epub 03/02. eng. doi:10.3892/or.2021.7954

Chen, Y., Yuan, S., Ning, T., Xu, H., and Guan, B. (2020). SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression. *Technology in Cancer Research & Treatment*.

Chen, Y., Peng, Y., Xu, Z., Ge, B., Xiang, Z., Zhang, T., et al. (2019). Knockdown of lncRNA SNHG7 Inhibited Cell Proliferation and Migration in Bladder Cancer through Activating Wnt/β-Catenin Pathway. *Pathol. – Res. Pract.* 215(2), 302–307. PubMed PMID: 30527338. Epub 2018/12/12. eng. doi:10.1016/j/prp.2018.11.015

Chen, Z., Liu, Z., Chen, S., and Jiang, H. (2019). Long Non-coding RNA SNHG7 Promotes the Fracture Repair through Negative Modulation of miR-9. *Am. J. Transl. Res.* 11(2), 974–982. PubMed PMID: 30899396. eng.

Chen, Z., He, M., Chen, J., Li, C., and Zhang, Q. (2020). Long Non-coding RNA SNHG7 1-nhibits NLRP3-dependent P-yroptosis by T-argeting the miR-34a/ SIRT1 axis in L-iwer C-ancer. *Oncol. Lett.* 20(1), 893–901. PubMed PMID: 32566017. Epub 05/18. eng. doi:10.3892/ol.2020.11635

Cheng, D., Fan, J., Ma, Y., Zhou, Y., Qin, K., Shi, M., et al. (2019). LncRNA SNHG7 Promotes Pancreatic Cancer Proliferation through ID4 by Sponging miR-342-3p. *Cell Biosci.* 9(1), 28–11. doi:10.1186/s13578-019-0290-2

Cheng, D., Fan, J., Qin, K., Zhou, Y., Yang, J., Ma, Y., et al. (2021). LncRNA SNHG7 Regulates Mesenchymal Stem Cell through the Notch1/Jagged1/Hes-1 Signaling Pathway and Influences Folfirinox Resistance in Pancreatic Cancer. *Front. Oncol.* 11(3235). doi:10.3389/fonc.2021.719855

Cheng, D., Fan, J., Ma, Y., Zhou, Y., Qin, K., Shi, M., et al. (2019). LncRNA SNHG7 Promotes Pancreatic Cancer Proliferation through ID4 by Sponging miR-342-3p. *Cell Biosci.* 9, 28. PubMed PMID: 30949340. Pubmed Central PMCID: PMC6431029. Epub 2019/04/06. eng. doi:10.1186/s13578-019-0290-2
Yao, X., Liu, C., Liu, C., Xi, W., Sun, S., and Gao, Z. (2019). lncRNA SNHG7 Promotes the Proliferation of Esophageal Cancer Cells and Inhibits its Apoptosis. *Eur. Rev. Med. Pharmacol. Sci.* 22 (9), 2653–2661. PubMed PMID: 29771415. Epub 2018/05/18. eng. doi:10.26355/eurrev_201805_14961

Xue, Y. H., and Ge, Y. Q. (2020). Construction of lncRNA Regulatory Networks Reveal the Key lncRNAs Associated with Pituitary Adenomas Progression. *Math. Biosci.* 17 (3), 2138–2149. PubMed PMID: 32233527. Epub 2020/04/03. eng. doi:10.1016/mbb.2020113

Yamada, A., Yu, P., Lin, W., Okugawa, Y., Boland, C. R., and Goel, A. (2018). A RNA-sequencing approach for the Identification of Novel Long Non-coding RNA Biomarkers in Colorectal Cancer. *Sci. Rep.* 8 (1), 575. PubMed PMID: 29330370. eng. doi:10.1038/s41598-017-18407-6

Yang, X., Sun, L., Wang, L., Yao, B., Mo, H., and Yang, W. (2019). LncRNA SNHG7 Serves as a Potential Biomarker on the Prognosis of Human Solid Tumors: A Meta-Analysis. *Cpb* 22 (11), 1501–1510. PubMed PMID: 33397232. Epub 2021/01/06. eng. doi:10.14174/jcb.2019.109386

Yao, X., Liu, C., Liu, C., Xi, W., Sun, S., and Gao, Z. (2019). lncRNA SNHG7 Sponges miR-425 to Promote Proliferation, Migration, and Invasion of Hepatic Carcinoma Cells via Wnt/β-catenin/EMT Signalling Pathway. *Cell Biochem Funct.* 37 (7), 525–533. PubMed PMID: 31478234. Epub 09/02. eng. doi:10.1002/cbf.3429

Yu, P., Zhang, W., Yang, M., Lu, Q., and Wu, H. (2021). LncRNA SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186. *Cmar* 12, 10163–10172. PubMed PMID: 33168781. eng. doi:10.2147/cmar.s270328

Zhang, L., Fu, Y., and Guo, H. (2019). c-Myc-Induced Long Non-coding RNA Small Nuclear RNA Host Gene 7 Regulates Glycysis in Breast Cancer. *J. Breast Cancer* 22 (4), 533–547. PubMed PMID: 31897328. eng. doi:10.4048/jbc.2019.22.e54

Zhang, P., Shi, L., Song, L., Long, Y., Yuan, K., Ding, W., et al. (2020). LncRNA CRINE and LncRNA SNHG7 Are Promising Biomarkers for Prognosis in Synchronous Colorectal Liver Metastasis Following Hepatectomy. *Cmar* 12, 1681–1692. PubMed PMID: 32210611. eng. doi:10.2147/cmar.s233147

Zhao, J., Wang, W., Zhu, W., Dong, J., Cheng, Y., Yin, Z., et al. (2019). Mechanisms and Functions of Long Non-coding RNAs at Multiple Regulatory Levels. *Jnvs* 20 (22), 2573. PubMed PMID: 31712766. eng. doi:10.3930/jnvs.20225573

Zheng, Y., Yuan, Y., Zhang, Y., Cheng, L., Zhou, X., and Chen, K. (2020). SNHG7 Accelerates Cell Migration and Invasion through Regulating miR-34a-Snail-EMT axis in Gastric Cancer. *Cell Cycle* 19 (1), 142–152. doi:10.1080/15384101.2019.1699753

Zhu, Y., Qian, X. H., Ji, G. Z., and Yang, L. H. (2021). Clinicopathological and Prognostic Value of Long Noncoding RNA SNHG7 in Cancer Patients: a Meta-Analysis. *Ijms* 20 (22), 5573. PubMed PMID: 31712753. eng. doi:10.3390/ijms20225573

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Najafi, Ghafouri-Fard, Hussen, Jamal, Taheri and Hallajnejad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.